As part of the agreement, the companies have established a new AI co-innovation hub in London, bringing together AWS engineers, AI specialists and applied scientists with Novo Nordisk’s research and development teams to explore ways of shortening the journey from drug target identification to the first human dose.

The partnership combines Novo Nordisk’s scientific and therapeutic expertise with AWS’s cloud infrastructure, AI capabilities and technologies designed for the life sciences industry. The companies aim to use these capabilities to process complex datasets and support faster decision-making throughout early-stage drug discovery.

Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner. The agreement builds on an existing relationship between the two companies, which has already delivered productivity improvements across Novo Nordisk’s operations.

According to Novo Nordisk, the collaboration has helped reduce clinical documentation time and supported more than 25,000 employees with AI-enabled tools designed to improve productivity. The expanded partnership will now focus more strongly on research, development and the wider use of AI across the organization.

AWS technologies including Amazon Bio Discovery and Amazon Bedrock will be used to support areas such as identifying potential drug targets and designing new therapies. The companies also plan to connect genomic, imaging and clinical data to help researchers generate insights that can potentially influence clinical trial design.

Novo Nordisk will also leverage Amazon Bedrock AgentCore to develop AI agents that can automate and streamline selected operational processes. This shows that the partnership extends beyond laboratory research and into broader business and technology workflows.

The London hub is expected to provide a collaborative environment where pharmaceutical scientists and AI experts can work directly on real-world drug-development challenges. This could help move promising AI applications from experimentation toward practical use within pharmaceutical R&D.

The partnership reflects a wider shift across the pharmaceutical industry, where companies are increasingly using AI to manage complex biological datasets, identify patterns, improve research productivity and support drug-development decisions.

For Novo Nordisk, the strategic relationship with AWS represents an effort to make AI a core part of its innovation infrastructure. For AWS, the collaboration strengthens its position as a technology partner for pharmaceutical companies seeking to apply advanced AI and cloud computing to drug discovery.

Ultimately, the companies are aiming to compress drug-discovery timelines while maintaining the scientific and security standards required in pharmaceutical development. The success of the partnership will depend on how effectively AI-generated insights can translate into validated targets, clinical candidates and, eventually, new medicines for patients.